Edgewise Therapeutics, Inc.
A clinical-stage biopharmaceutical company in Boulder, Colorado that makes swallowed pills designed to treat serious muscle diseases. Its drugs tune myosin, the protein that drives muscle contraction, to protect fragile fibers in muscular dystrophies and to ease the stiff, thickened heart muscle of hypertrophic cardiomyopathy. Founded in 2017 by four scientists and drug developers, the company went public on Nasdaq in 2021.
Bought 951.3K
Bought 951.3K
Granted 48.4K · Sold 25.0K
Granted 400.6K · Sold 562.0K
Granted 115.5K · Sold 115.5K
Granted 272.3K · Sold 220.0K
Granted 151.6K · Sold 165.5K
Granted 78.3K · Sold 68.0K
Granted 3.0K · Bought 21.6K
Granted 117.0K · Sold 115.2K
Granted 29.7K · Sold 29.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Orbimed Advisors LLC +2 co-filersDirector, 10% owner · 3 transactions | — | 15.25Mas of Apr 2025 | — | 951.3K | — |
| Thompson Peter A.Director, 10% owner · 3 transactions | — | 15.25Mas of Apr 2025 | — | 951.3K | — |
| Koch KevinPresident and CEO, Director · 12 transactions | — | 403.8Kas of Aug 2025 | 48.4K | — | 25.0K |
| Russell Alan JChief Scientific Officer, Director · 22 transactions | -30% | 123.4K | 400.6K | — | 562.0K |
| Edris BadreddinDirector · 10 transactions | +388.2% | 96.8K | 115.5K | — | 115.5K |
| Carruthers R MichaelChief Financial Officer · 15 transactions | +196.9% | 86.2Kas of Aug 2025 | 272.3K | — | 220.0K |
| Donovan Joanne M.CMO · 18 transactions | +445.9% | 54.4K | 151.6K | — | 165.5K |
| Derakhshan BehradChief Business Officer · 16 transactions | +272.3% | 26.1Kas of Aug 2025 | 78.3K | — | 68.0K |
| Fox Jonathan CDirector · 7 transactions | — | 24.5K | 3.0K | 21.6K | — |
| Moore John RGeneral Counsel · 17 transactions | +87.5% | 12.3Kas of Aug 2025 | 117.0K | — | 115.2K |
| Semigran MarcChief Development Officer · 3 transactions | — | 6.7Kas of Dec 2024 | 29.7K | — | 29.7K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +623.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.